{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:49:28Z","timestamp":1761594568565,"version":"build-2065373602"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"DOI":"10.7759\/cureus.95523","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:45:26Z","timestamp":1761594326000},"source":"Crossref","is-referenced-by-count":0,"title":["Unmasking Dual Vascular Complications of Sunitinib in Advanced Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Stella","family":"Nabirye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Nakagaayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmy","family":"Okello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.72748","article-title":"Epidemiology and treatment outcomes of renal cell carcinoma in Qassim Region, Saudi Arabia: a retrospective study","volume":"16","author":"Alharbi B","year":"2024","unstructured":"Alharbi B, Alnosayan HS, Al-Harbi FA, et al.. Epidemiology and treatment outcomes of renal cell carcinoma in Qassim Region, Saudi Arabia: a retrospective study. Cureus. 2024, 16:e72748. 10.7759\/cureus.72748","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023, 8:262. 10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger M","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM, et al.. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008, 26:5204-12. 10.1200\/JCO.2007.15.6331","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri TK","year":"2010","unstructured":"Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010, 28:2280-5. 10.1200\/JCO.2009.27.2757","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02928.x","article-title":"Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis","volume":"6","author":"Iodice S","year":"2008","unstructured":"Iodice S, Gandini S, L\u00f6hr M, Lowenfels AB, Maisonneuve P. Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis. J Thromb Haemost. 2008, 6:781-8. 10.1111\/j.1538-7836.2008.02928.x","journal-title":"J Thromb Haemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak NB","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018, 10:380. 10.3390\/cancers10100380","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225382","article-title":"The role of anticoagulation in tumor thrombus associated with renal cell carcinoma: a literature review","volume":"15","author":"Williams CM","year":"2023","unstructured":"Williams CM, Myint ZW. The role of anticoagulation in tumor thrombus associated with renal cell carcinoma: a literature review. Cancers (Basel). 2023, 15:5382. 10.3390\/cancers15225382","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-30","article-title":"Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma","volume":"28","author":"Tsimafeyeu IV","year":"2009","unstructured":"Tsimafeyeu IV, Demidov LV, Madzhuga AV, Somonova OV, Yelizarova AL. Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2009, 28:30. 10.1186\/1756-9966-28-30","journal-title":"J Exp Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski R Jr","year":"2007","unstructured":"Roskoski R Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007, 356:323-8. 10.1016\/j.bbrc.2007.02.156","journal-title":"Biochem Biophys Res Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2018.01.003","article-title":"Arterial thrombosis and cancer","volume":"164 Suppl 1","author":"Aronson D","year":"2018","unstructured":"Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res. 2018, 164 Suppl 1:S23-8. 10.1016\/j.thromres.2018.01.003","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2450\/2015.0335-14","article-title":"Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria","volume":"13","author":"Ahmed SG","year":"2015","unstructured":"Ahmed SG, Kagu MB, Ibrahim UA, Bukar AA. Impact of sickle cell trait on the thrombotic risk associated with non-O blood groups in northern Nigeria. Blood Transfus. 2015, 13:639-43. 10.2450\/2015.0335-14","journal-title":"Blood Transfus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000694","article-title":"Sickle cells and sickle trait in thrombosis","volume":"133","author":"Kato GJ","year":"2019","unstructured":"Kato GJ. Sickle cells and sickle trait in thrombosis. Blood. 2019, 133:2463. 10.1182\/blood.2019000694","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12787","article-title":"Prospective study of sickle cell trait and venous thromboembolism incidence","volume":"13","author":"Folsom AR","year":"2015","unstructured":"Folsom AR, Tang W, Roetker NS, et al.. Prospective study of sickle cell trait and venous thromboembolism incidence. J Thromb Haemost. 2015, 13:2-9. 10.1111\/jth.12787","journal-title":"J Thromb Haemost"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015674","article-title":"Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model","volume":"9","author":"Trebak F","year":"2025","unstructured":"Trebak F, Sako MO, Grover SP, et al.. Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model. Blood Adv. 2025, 9:2709-21. 10.1182\/bloodadvances.2024015674","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.12.008","article-title":"De-escalation of antiplatelet therapy in patients with coronary artery disease: time to change our strategy?","volume":"110","author":"Sabouret P","year":"2023","unstructured":"Sabouret P, Spadafora L, Fischman D, et al.. De-escalation of antiplatelet therapy in patients with coronary artery disease: time to change our strategy?. Eur J Intern Med. 2023, 110:1-9. 10.1016\/j.ejim.2022.12.008","journal-title":"Eur J Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1626-2-9082","article-title":"Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report","volume":"2","author":"Batra R","year":"2009","unstructured":"Batra R, Davies JN, Wheatley D. Extensive arterial and venous thrombo-embolism with chemotherapy for testicular cancer: a case report. Cases J. 2009, 2:9082. 10.1186\/1757-1626-2-9082","journal-title":"Cases J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.180852","article-title":"Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on sunitinib","volume":"53","author":"Ahmad M","year":"2016","unstructured":"Ahmad M, Prasad S, Krishna MV, Lavingia V. Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on sunitinib. Indian J Cancer. 2016, 53:112-3. 10.4103\/0019-509X.180852","journal-title":"Indian J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.15836\/ccar2022.384","article-title":"Zaputovi\u0107, acute coronary syndrome in a patient on tyrosine kinase inhibitor therapy-case report","volume":"17","author":"Spicijari\u0107 M","year":"2022","unstructured":"Spicijari\u0107 M, Tomuli\u0107 V, Zaputovi\u0107 L. Zaputovi\u0107, acute coronary syndrome in a patient on tyrosine kinase inhibitor therapy-case report. Cardiol Croatica. 2022, 17:384-9. 10.15836\/ccar2022.384","journal-title":"Cardiol Croatica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002668","article-title":"Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions","volume":"86","author":"Al-Hasnawi Z","year":"2024","unstructured":"Al-Hasnawi Z, Hasan HM, Abdul Azeez JM, et al.. Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions. Ann Med Surg (Lond). 2024, 86:7212-20. 10.1097\/MS9.0000000000002668","journal-title":"Ann Med Surg (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406972-unmasking-dual-vascular-complications-of-sunitinib-in-advanced-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:45:27Z","timestamp":1761594327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406972-unmasking-dual-vascular-complications-of-sunitinib-in-advanced-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.95523","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}